MacuMira® Treatment for Dry Macular Degeneration (AMD) in Sydney
A New, Non-Invasive Treatment Option for Dry AMD and Geographic Atrophy
MacuMira® is an innovative, non-invasive treatment designed for patients with dry age-related macular degeneration (AMD), particularly those with geographic atrophy (GA) – a condition where treatment options have historically been limited.
At Pure Sight Eye Surgeons, we are among the first clinics in Australia to offer MacuMira technology, reflecting our commitment to providing patients with access to advanced, state-of-the-art retinal treatments.
What is MacuMira?
MacuMira is a TGA-approved microcurrent stimulation therapy that delivers low-level electrical stimulation to the retina.
This gentle stimulation is designed to:
- Support retinal cell function
- Enhance cellular activity and metabolism
- Improve visual performance in selected patients
Unlike injections or surgery, MacuMira is:
- Non-invasive
- Performed in the clinic
- Well tolerated by patients
Who is MacuMira suitable for?
MacuMira may be considered for patients with:
- Dry macular degeneration (dry AMD)
- Geographic atrophy (GA)
- Reduced vision affecting daily activities (e.g. reading, recognising faces)
Patients with moderate levels of vision reduction often experience the greatest functional benefit, although suitability varies.
A comprehensive retinal assessment is required, including:
- Optical coherence tomography (OCT)
- Visual acuity testing
- Contrast sensitivity testing
What does the treatment involve?
MacuMira treatment is delivered as a short loading course:
- 4 treatment sessions
- Over approximately 10 days
- Each session lasts around 30–40 minutes
The treatment is performed in a comfortable clinical setting, with no injections or surgical intervention required.
Depending on individual response, maintenance treatments may be recommended at intervals to help sustain the benefits over time. This is determined on a case-by-case basis following review and monitoring.
What results can be expected?
MacuMira is not a cure for macular degeneration and does not reverse established retinal damage.
However, in selected patients, it may:
- Improve visual clarity
- Enhance contrast sensitivity
- Support functional vision (e.g. reading ability)
We monitor outcomes closely using:
- OCT imaging
- Visual acuity testing
- Contrast sensitivity
This allows us to objectively assess response and guide ongoing care.
Why choose Pure Sight Eye Surgeons for MacuMira?
- Among the first clinics in Australia to offer MacuMira
- Specialist ophthalmology-led care
- Expertise in medical retina and macular disease
- Access to advanced imaging and diagnostic technology
- Integrated care pathway for macular degeneration
We focus on individualised treatment, ensuring each patient receives the most appropriate combination of monitoring, medical therapy, and emerging technologies.
MacuMira vs Other AMD Treatments
- Dry AMD: traditionally limited to monitoring and lifestyle measures
- Wet AMD: treated with intravitreal injections (anti-VEGF therapy)
MacuMira introduces a new, non-invasive option for dry AMD, addressing a long-standing gap in treatment.
Learn more about
- Macular degeneration diagnosis and management (internal link)
- Intravitreal injections for wet AMD (internal link)
Frequently Asked Questions
Is MacuMira available in Australia?
Yes. MacuMira is TGA-approved and available in a limited number of clinics. Pure Sight Eye Surgeons is among the early providers offering this treatment in Australia.
Is MacuMira painful?
No. The treatment is non-invasive and generally well tolerated, with no injections or surgical procedures involved.
How long does MacuMira treatment take?
Each session takes approximately 30–40 minutes, with a typical course consisting of four treatments over 10 days.
Will MacuMira cure macular degeneration?
No. MacuMira does not cure AMD or reverse established damage. Its role is to support retinal function and improve visual performance in selected patients.
Do I still need monitoring after treatment?
Yes. Ongoing monitoring is essential in all patients with macular degeneration. We tailor follow-up based on your individual condition and response to treatment.
How long has MacuMira been around?
MacuMira is a relatively new and emerging technology that has been introduced into clinical practice in recent years. It was initially adopted in Canada and is now being used in a growing number of more than 200 clinics internationally, including Australia.
As with many new medical technologies, clinical experience continues to evolve, with increasing adoption and ongoing research helping to define its role in the management of dry macular degeneration.
What is the evidence for MacuMira?
MacuMira is supported by early clinical experience and ongoing research evaluating its role in improving visual function in patients with dry macular degeneration.
Current evidence includes:
- Real-world clinical use across multiple international centres
- Ongoing clinical studies assessing visual outcomes and retinal function
- Research exploring retinal metabolic and oxygenation changes
MacuMira represents a developing area of retinal therapy, where early clinical experience is promising but ongoing studies are continuing to refine its role in patient care.
For this reason, careful patient selection, baseline assessment, and follow-up monitoring are essential.
We take a cautious, evidence-informed approach to new technologies, integrating them into practice where they offer potential benefit while continuing to monitor outcomes carefully.
Book a Consultation
If you have been diagnosed with dry macular degeneration or geographic atrophy, and are interested in exploring new treatment options, we recommend a comprehensive assessment.
Our team will determine whether MacuMira or other treatment pathways are appropriate for your condition.
Book a consultation at Pure Sight Eye Surgeons – link to healthengine